Top
Main

All Outcomes

Feedback
Home
Show Outline
Top   Main   All Outcomes
Home   COVID-19 treatment studies for Curcumin  COVID-19 treatment studies for Curcumin  C19 studies: Curcumin  Curcumin   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
Loading...
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc
Supplementary Data — Curcumin for COVID-19: real-time meta analysis of 21 studies
Covid Analysis, December 2022
https://c19early.org/tmeta.html
 
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Dound (RCT) 33% 0.67 [0.54-0.82] 6 pt. scale 100 (n) 100 (n) CT​1 Improvement, RR [CI] Treatment Control Saber-Moghaddam 94% 0.06 [0.00-0.93] progression 0/21 8/20 Saber-Moghaddam 38% 0.62 [0.39-0.96] no recov. 11/21 17/20 Saber-Moghaddam 45% 0.55 [0.39-0.79] hosp. time 21 (n) 20 (n) Aldwihi 31% 0.69 [0.43-1.04] hosp. 30/144 207/594 Pawar (DB RCT) 82% 0.18 [0.04-0.79] death 2/70 11/70 Pawar (DB RCT) 60% 0.40 [0.09-1.75] death 2/15 5/15 Pawar (DB RCT) 91% 0.09 [0.01-1.56] death 0/25 5/25 Pawar (DB RCT) 67% 0.33 [0.01-7.87] death 0/30 1/30 Ahmadi (DB RCT) 86% 0.14 [0.01-2.65] hosp. 0/30 3/30 Ahmadi (DB RCT) 21% 0.79 [0.48-1.31] recov. time 30 (n) 30 (n) Sankhe (RCT) 89% 0.11 [0.01-2.03] death 0/87 4/87 CT​1 Sankhe (RCT) 75% 0.25 [0.03-2.19] ventilation 1/87 4/87 CT​1 Sankhe (RCT) 46% 0.54 [0.35-0.76] no recov. 29/87 60/87 CT​1 Sankhe (RCT) 10% 0.90 [0.71-1.15] hosp. time 87 (n) 87 (n) CT​1 Majeed (DB RCT) 66% 0.34 [0.01-8.09] ventilation 0/45 1/47 CT​1 Majeed (DB RCT) 80% 0.20 [0.01-4.13] hosp. 0/45 2/47 CT​1 Majeed (DB RCT) 43% 0.57 [0.39-0.84] no recov. 45 (n) 47 (n) CT​1 Majeed (DB RCT) 25% 0.75 [0.56-1.01] no recov. 26/45 36/47 CT​1 Majeed (DB RCT) 6% 0.94 [0.80-1.10] viral time 45 (n) 47 (n) CT​1 Khan (RCT) 33% 0.67 [0.37-1.19] no recov. 10/25 15/25 CT​1 Khan (RCT) 39% 0.61 [0.43-0.87] no recov. 25 (n) 25 (n) CT​1 Khan (RCT) 50% 0.50 [0.30-0.84] viral+ 10/25 20/25 CT​1 Askari (DB RCT) -125% 2.25 [0.30-16.6] no recov. 3/8 1/6 Askari (DB RCT) -433% 5.33 [0.30-93.3] no recov. 2/6 0/7 Askari (DB RCT) 73% 0.27 [0.07-1.03] no recov. 2/12 8/13 Askari (DB RCT) 40% 0.60 [0.20-1.77] no recov. 3/10 7/14 Askari (DB RCT) 38% 0.62 [0.21-1.79] no recov. 4/13 4/8 Askari (DB RCT) -71% 1.71 [0.20-14.5] no recov. 2/7 1/6 Askari (DB RCT) 12% 0.88 [0.07-11.5] no recov. 1/8 1/7 Askari (DB RCT) 0% 1.00 [0.25-4.07] no recov. 3/13 3/13 Valizadeh (DB RCT) 50% 0.50 [0.18-1.40] death 4/20 8/20 Tahmasebi (DB RCT) 83% 0.17 [0.02-1.32] death 1/40 6/40 Tahmasebi (DB RCT) 67% 0.33 [0.01-7.72] death 0/20 1/20 Tahmasebi (DB RCT) 80% 0.20 [0.03-1.56] death 1/20 5/20 Hassania.. (DB RCT) -46% 1.46 [0.01-329] SpO2 imp. 20 (n) 20 (n) Asadirad (RCT) 26% 0.74 [0.26-2.12] death 5/27 6/24 Asadirad (RCT) 50% 0.50 [0.14-1.82] progression 3/30 6/30 Asadirad (RCT) 45% 0.55 [0.27-1.09] no recov. 8/27 13/24 Asadirad (RCT) 29% 0.71 [0.22-2.35] no recov. 4/27 5/24 Asadirad (RCT) 41% 0.59 [0.25-1.42] no recov. 6/27 9/24 Asadirad (RCT) 37% 0.63 [0.23-1.74] no recov. 5/27 7/24 Asadirad (RCT) 20% 0.80 [0.58-1.10] no recov. 18/27 20/24 Kartika 41% 0.59 [0.35-1.00] hosp. time 139 (n) 107 (n) Hartono (RCT) 53% 0.47 [0.32-0.68] viral+ 14/30 30/30 CT​1 Hartono (RCT) 75% 0.25 [0.09-0.66] viral+ 4/30 16/30 CT​1 Hartono (RCT) 67% 0.33 [0.01-7.87] viral+ 0/30 1/30 CT​1 Thomas (DB RCT) 44% 0.56 [0.34-0.91] improv. 74 (n) 73 (n) LONG COVID CT​1 Thomas (DB RCT) 82% 0.18 [0.07-0.47] improv. 74 (n) 73 (n) LONG COVID CT​1 Thomas (DB RCT) 64% 0.36 [0.16-0.84] improv. 74 (n) 73 (n) LONG COVID CT​1 Sankhe (SB RCT) 86% 0.14 [0.01-2.71] death 0/60 3/60 CT​1 Sankhe (SB RCT) 86% 0.14 [0.01-2.71] ventilation 0/60 3/60 CT​1 Sankhe (SB RCT) 67% 0.33 [0.04-3.11] ICU 1/60 3/60 CT​1 Sankhe (SB RCT) 10% 0.90 [0.71-1.15] hosp. time 45 (n) 45 (n) CT​1 Sankhe (SB RCT) 17% 0.83 [0.63-1.10] hosp. time 15 (n) 15 (n) CT​1 Sankhe (SB RCT) 32% 0.68 [0.54-0.86] recov. time 45 (n) 45 (n) CT​1 Sankhe (SB RCT) 36% 0.64 [0.49-0.83] recov. time 45 (n) 45 (n) CT​1 Sankhe (SB RCT) 4% 0.96 [0.75-1.23] recov. time 15 (n) 15 (n) CT​1 Sankhe (SB RCT) -5% 1.05 [0.99-1.11] recov. time 15 (n) 15 (n) CT​1 Sankhe (SB RCT) 44% 0.56 [0.38-0.81] viral load 44 (n) 43 (n) CT​1 Hellou (DB RCT) 77% 0.23 [0.06-0.95] NEWS2 33 (n) 17 (n) CT​1 Hellou (DB RCT) 92% 0.08 [0.00-1.38] oxygen 0/33 4/17 CT​1 Hellou (DB RCT) 70% 0.30 [0.05-1.67] oxygen time 33 (n) 17 (n) CT​1 Hellou (DB RCT) 13% 0.87 [0.07-10.6] hosp. time 33 (n) 17 (n) CT​1 Hellou (DB RCT) 10% 0.90 [0.47-1.71] viral+ 14/33 8/17 CT​1 Abbaspour-A.. (RCT) 71% 0.29 [0.06-1.26] death 2/30 7/30 Abbaspour-A.. (RCT) 86% 0.14 [0.02-1.06] no recov. 1/28 6/23 Abbaspour-A.. (RCT) 90% 0.10 [0.01-1.79] no recov. 0/28 4/23 Abbaspour-A.. (RCT) 38% 0.62 [0.32-1.20] no recov. 9/28 12/23 Abbaspour-A.. (RCT) 59% 0.41 [0.12-1.46] no recov. 3/28 6/23 Abbaspour-A.. (RCT) 82% 0.18 [0.01-3.65] no recov. 0/28 2/23 Shehab 42% 0.58 [0.14-2.32] severe case 2/32 24/221 Nimer 31% 0.69 [0.45-1.04] hosp. 29/329 179/1,819 Nimer 13% 0.87 [0.61-1.24] severe case 40/329 211/1,819 Curcumin COVID-19 outcomes c19early.org/t Dec 2022 1 CT: study uses combined treatment Favors curcumin Favors control
Figure S1. All outcomes.
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit